ARQT Arcutis Biotherapeutics Inc

Price (delayed)

$11.77

Market cap

$1.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.78

Enterprise value

$1.26B

Arcutis Biotherapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent ...

Highlights
ARQT's EPS is up by 33% YoY and by 13% QoQ
The company's revenue rose by 22% QoQ
Arcutis Biotherapeutics's equity has surged by 90% QoQ but it has shrunk by 58% YoY
Arcutis Biotherapeutics's quick ratio has decreased by 42% YoY but it has increased by 8% QoQ

Key stats

What are the main financial stats of ARQT
Market
Shares outstanding
96.81M
Market cap
$1.14B
Enterprise value
$1.26B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.53
Price to sales (P/S)
13.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.07
Earnings
Revenue
$59.61M
EBIT
-$229.32M
EBITDA
-$227.43M
Free cash flow
-$247.49M
Per share
EPS
-$3.78
Free cash flow per share
-$3.57
Book value per share
$0.94
Revenue per share
$0.86
TBVPS
$4.83
Balance sheet
Total assets
$341.37M
Total liabilities
$252.7M
Debt
$205.92M
Equity
$88.67M
Working capital
$283.76M
Liquidity
Debt to equity
2.32
Current ratio
7.08
Quick ratio
6.4
Net debt/EBITDA
-0.51
Margins
EBITDA margin
-381.6%
Gross margin
91.6%
Net margin
-439.8%
Operating margin
-404.5%
Efficiency
Return on assets
-78.6%
Return on equity
-294.9%
Return on invested capital
-58.1%
Return on capital employed
-77.8%
Return on sales
-384.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARQT stock price

How has the Arcutis Biotherapeutics stock price performed over time
Intraday
14.49%
1 week
21.59%
1 month
77.26%
1 year
-29.48%
YTD
264.4%
QTD
264.4%

Financial performance

How have Arcutis Biotherapeutics's revenue and profit performed over time
Revenue
$59.61M
Gross profit
$54.62M
Operating income
-$241.1M
Net income
-$262.14M
Gross margin
91.6%
Net margin
-439.8%
Arcutis Biotherapeutics's net margin has surged by 95% YoY and by 19% QoQ
The operating margin has soared by 95% YoY and by 20% from the previous quarter
The company's revenue rose by 22% QoQ
The company's operating income rose by 20% YoY and by 2.9% QoQ

Growth

What is Arcutis Biotherapeutics's growth rate over time

Valuation

What is Arcutis Biotherapeutics stock price valuation
P/E
N/A
P/B
12.53
P/S
13.69
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
21.07
ARQT's EPS is up by 33% YoY and by 13% QoQ
The stock's price to book (P/B) is 167% more than its 5-year quarterly average of 4.7 and 124% more than its last 4 quarters average of 5.6
Arcutis Biotherapeutics's equity has surged by 90% QoQ but it has shrunk by 58% YoY
The price to sales (P/S) is 67% lower than the last 4 quarters average of 41.2
The company's revenue rose by 22% QoQ

Efficiency

How efficient is Arcutis Biotherapeutics business performance
The ROE has plunged by 120% YoY and by 31% from the previous quarter
ARQT's ROS has soared by 95% YoY and by 20% QoQ
The company's return on invested capital rose by 14% YoY but it fell by 6% QoQ
ARQT's return on assets is down by 6% since the previous quarter and by 2.3% year-on-year

Dividends

What is ARQT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARQT.

Financial health

How did Arcutis Biotherapeutics financials performed over time
ARQT's total assets is 35% greater than its total liabilities
Arcutis Biotherapeutics's quick ratio has decreased by 42% YoY but it has increased by 8% QoQ
The current ratio has contracted by 39% YoY but it has grown by 5% from the previous quarter
Arcutis Biotherapeutics's debt is 132% higher than its equity
ARQT's debt to equity has surged by 139% year-on-year but it is down by 47% since the previous quarter
Arcutis Biotherapeutics's equity has surged by 90% QoQ but it has shrunk by 58% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.